This analysis compares interleukin-37 levels in chronic hepatitis B patients, spontaneously cleared cases, and healthy controls, suggesting potential therapeutic implications.
Background: Interleukin-37 (IL-37) can prevent liver damage and may be an important candidate for use as a novel therapeutic tool in hepatitis B virus (HBV) infection. This study aimed to evaluate the serum levels of IL-37 in individuals with chronic HBV (CHB) infection, those who spontaneously cleared (SC) HBV infection, compared with healthy control (HC) subjects.
No takes yet. Share an insight, caveat, or question.
Khansalar et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: